Adipogenesis is dependent on the sequential activation of transcription factors including the CCAAT/enhancer binding proteins (C/EBP) 1 , peroxisome proliferator-activated receptor gamma (PPARg), and steroid regulatory element binding protein (SREBP). We show that the mood stabilizing drug valproic acid (VPA; 0.5-2 mM) inhibits mouse 3T3 L1 and human preadipocyte differentiation, likely through its histone deacetylase (HDAC) inhibitory properties. The HDAC inhibitor trichostatin A (TSA) also inhibited adipogenesis, whereas the VPA analog valpromide (VPM), which does not possess HDAC inhibitory effects, did not prevent adipogenesis. Acute or chronic VPA treatment inhibited differentiation yet did not affect mitotic clonal expansion. VPA
Introduction
Valproic acid (VPA) has been used as an anticonvulsant agent for the treatment of epilepsy, as well as a mood stabilizer for the treatment of bipolar disorder, for several decades. Overall VPA is well tolerated, with common side effects including tremor, sedation, alopecia, and weight gain (1) . The mechanism of action for these efficacious and deleterious effects remains to be elucidated and is most likely multifactorial. The specific effects of VPA on neurotransmitter systems, most notably GABA signaling, as well as other cell signaling pathways explains some of the mechanisms by which VPA exerts its effects in humans, rodents, and cell culture systems (2) . For example, VPA has histone deacetylase (HDAC) inhibitory effects that are the likely cause of VPA teratogenicity (3, 4) . In addition, inositol depletion contributes to VPA inhibition of sensory neuronal growth cone formation in vitro (5) .
Up to 70% of adult patients receiving VPA treatment gain weight (5-14 kgs.) (6) . This is cause for concern due to the increasing number of off-label uses for VPA, such as migraine headache and neuropathic pain, and the increased health risk and decreased compliance rate associated with weight gain (6) (7) (8) . Clinically evaluating patient age, sex, familial predisposition to weight gain, changes in dietary habits, and VPA dosage have failed to reveal predictive factors for VPA-induced weight gain. In attempting to generate animal models of VPA-induced weight gain, we and others have demonstrated that VPA does not cause weight gain in mice (9) or rats (10, 11) , however VPA can induce a significant increase in body weight in female rhesus monkeys (12) , suggesting that this side-effect may be a characteristic of primate physiology.
There is currently no clear mechanism to explain how VPA causes weight gain.
VPA can inhibit both class I and II HDACs, with a high potency for class I HDACs (4) . The role of HDAC activity in adipocyte differentiation is not well defined, however recent work has highlighted a requirement for reduced HDAC activity for transcriptional activation of adipogenic genes in vitro (13) . We demonstrate that VPA treatment inhibits mouse 3T3-L1 and human adipocyte differentiation. Adipocytes differentiate from preadipocytes via a well-defined series of transcriptional events involving several key transcription factors, including members of the CCAAT/enhancer binding protein (C/EBP) family, peroxisome proliferator-activated receptor gamma (PPARg) and steroid regulatory element binding protein (SREBP) (14) . Inhibition of differentiation by VPA is characterized by diminished PPARg and SREBP1a mRNA and protein.
The mRNA levels for C/EBPa were not affected by VPA treatment, however there was a significant reduction in C/EBPa protein levels. Experiments using either the structurally unrelated HDAC inhibitor trichostatin A (TSA) or valpromide (VPM), an amide analog of VPA that does not inhibit HDACs, support the hypothesis that HDAC activity is required for initiation of adipogenesis.
Experimental Procedures

Cell culture and differentiation
Mouse 3T3-L1 were obtained from the American Type Culture Collection and subcultured in 5% CO 2 at 37 0 C. Cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM; Invitrogen), with 10% heat inactivated calf serum (Invitrogen) and penicillin G/streptomycin sulfate (Invitrogen). Media was changed every two days and preadipocytes were maintained at <50% confluence.
For 3T3-L1 differentiation experiments, 2 days after preadipocytes reached confluence they were treated with medium to induce differentiation [MDI: DMEM, 10% fetal bovine serum (FBS; CanSera), 250 nmol/L dexamethasone (DEX; Sigma), 0.5 nmol/L 3-isobutyl-1- Cells were then washed with absolute alcohol at room temperature (RT) and allowed to air dry at RT for 2 h. DNA was extracted using 0.1M NaOH for at least 1 h at RT and radioactivity was counted in acidified scintillation fluid. Twenty hours after addition of drugs cells were harvested and luciferase activity determined using the Enhanced Luciferase Assay kit (BD Pharmingen). Results were normalized using bgalactosidase activity and represent the mean data from three independent experiments.
Analysis of lipid synthesis
Results
VPA inhibits adipocyte differentiation
To determine whether VPA could induce adipocyte differentiation, mouse 3T3-L1 cells were cultured for two days in DMEM medium containing 10% FBS, insulin and VPA (1 or 5 mM).
After 13 days in culture there were very few cells staining red with Oil Red O, which binds to triacylglycerol (TAG) in fat droplets, a hallmark of adipocyte formation ( Figure 1A , left panel; higher magnification 1B). As a positive control, cells induced to differentiate in medium consisting of DMEM containing 10% FBS, IBMX, dexamethasone (0.25 µM) and insulin (MDI) but no VPA, contained numerous lipid droplets ( Figure 1A ). These data show that chronic VPA treatment was unable to induce differentiation of 3T3-L1 cells into adipocytes.
We next examined the effect of VPA treatment on MDI-induced preadipocyte differentiation. In addition to working with 3T3-L1 cells, Zen-Bio Inc. were contracted to conduct a doubleblind study to examine the effects of VPA on differentiation of primary human subcutaneous preadipocyte cultures in vitro. Similar to the studies in 3T3-L1 cells, the effect of VPA on adipocyte differentiation was measured both in the absence and presence of differentiation inducing media (Zen-DIM). These studies were conducted on two cell lots, one from a single individual (L091901) and the other from a pooled sample containing adipocytes from 6 individuals (SL0023). In both lots VPA by itself did not induce differentiation of human preadipocytes, rather it inhibited differentiation in the presence of Zen-DIM ( Figure 2A ). Lot L091901 exhibited some differentiation in the absence of Zen-DIM, which was also inhibited by VPA treatment (Figure 2A ). Quantification of TAG levels revealed that VPA inhibited differentiation in a dose dependent manner more effectively than tumor necrosis factor a, a known inhibitor of preadipocyte differentiation ( Figure 2B ). Collectively these data show that in both mouse and human cells chronic VPA treatment inhibits adipocyte differentiation.
We then examined whether the inhibitory effects of VPA on 3T3-L1 differentiation occurred following a single (acute) treatment with VPA. When 1 mM VPA was added once concurrent with MDI at the onset of differentiation, VPA reduced adipocyte formation ( Figure 3A ). This Figure 3C ). Daily VPA treatment beginning 7 days after the initiation of differentiation (day 7-13) also reduced Oil Red O levels, however this reduction was not significant compared to untreated cells. These results suggest that VPA is affecting critical events that occur both at the onset of differentiation, as well as events required during the initial maturation of the adipocytes.
VPA inhibits PPARg-induced differentiation
PPARg agonists induce differentiation of adipocytes, whereas PPARg antagonists inhibit differentiation (17) . The PPARg ligands troglitazone (TGZ) and the more potent rosiglitazone (ROS) were used to induce differentiation of 3T3-L1 and human preadipocytes. When co-treated with VPA and either TGZ or ROS, differentiation of 3T3-L1 cells was inhibited by 60% and 43% respectively ( Figure 4A ), suggesting that VPA can inhibit differentiation mediated by
PPARg. In support of these findings, VPA was also able to inhibit ROS-induced differentiation of human preadipocytes; assessed by TAG levels ( Figure 4B ). Furthermore, VPA inhibited differentiation of human preadipocytes when differentiation was induced with 10 µM Zen-Bio proprietary non-thiazolidinedione PPARg agonist 2 . These data show that VPA inhibits PPARginduced differentiation in mouse and human preadipocytes.
VPA is not a PPARg ligand
Due to VPA's ability to block PPARg-induced differentiation, we conducted reporter assays to assess whether VPA interacted with the ligand binding domain (LBD) of PPARg. Since TGZ and ROS had equivalent activities, these experiments were conducted using TGZ. VPA induced a weak activation of the PPARg-LBD chimeric construct (PPAR-Gal4), compared to a greater than 40 fold increase by TGZ ( Figure 4C ). The VPA-induced fold increase in PPAR-Gal4 was similar to the increase in activation of the control plasmid (BD-Gal4) lacking the PPARg-LBD.
These results suggest that VPA may non-specifically increase the activation of PPAR-Gal4. VPA increases the activity of many reporter genes in transient transfection experiments and is suggested to be due to VPA acting as a HDAC inhibitor (4). We found that the HDAC inhibitor TSA induces a similar fold increase as VPA in BD-Gal4 and PPAR-Gal4 reporter activity ( Figure 4C ). These data suggest that non-specific activation of reporter genes may be due to an indirect effect of HDAC inhibitors.
PPARg partial agonists or antagonists can inhibit 3T3-L1 differentiation. Since VPA inhibits 3T3-L1 differentiation, we examined the effect of VPA on the dose response curve for TGZinduced PPARg activity to determine whether VPA may be acting as a PPARg partial agonist or antagonist. TGZ dose-dependently induced PPARg activity with a mean fold induction of luciferase activity ranging from 23±2.5 to 35±5.2 ( Figure 4D ). If VPA was acting as a partial agonist or antagonist it should inhibit TGZ activity. VPA induced a mean 2.5±0.23 fold increase ( Figure 4F ) in TGZ-induced PPARg activity [range: 53±6.3 to 72±16.0 ( Figure 4D )], however, this fold increase by VPA was similar to the increase in BD-Gal4 reporter activity ( Figure 4E and F). Unlike VPA, TGZ did not induce the control BD-Gal4 reporter. TSA had similar effects as VPA in inducing an ~2 fold increase in TGZ-activated PPARg and BD-Gal4 reporter activity 3 .
These data implies that VPA (0.5-2 mM) does not act as a PPARg partial agonist or antagonist, most likely producing its effects through its HDAC inhibitory activity.
VPA treatment inhibits PPARg and SREBP1a mRNA levels
The onset of differentiation in adipocytes involves activation of gene expression including C/EBPa/ß/d, PPARg, and SREBP1a. Northern analysis was conducted to determine whether the reduction in differentiation by VPA was accompanied by changes in gene expression. Prior to the onset of differentiation preadipocytes have undetectable levels of C/EBPa, PPARg, and SREBP1a mRNA ( Figure 5A ). Twenty-four hours following the initiation of differentiation a weak signal for the three transcripts was detectable. At day 1, 2 and 5 following the initiation of differentiation, VPA-treated cells had reduced levels of PPARg and SREBP1a mRNA, and no change in C/EBPa mRNA levels compared to control cells ( Figure 5A & B). We found that VPA reduced GAPDH mRNA levels at day 2 and 5 days by 33±6% and 29±8%, respectively, and therefore could not use it to normalize for equal loading. Since there was no change in C/EBPa levels at day 2 and 5 following treatment, it is unlikely that the reduction in PPARg and SREBP1a gene expression is due to unequal loading; confirmed by 18S rRNA loading ( Figure   5A ).
VPA treatment reduces PPARg, SREBP1a and C/EBPa protein levels
In order to determine if VPA-induced a concomitant reduction in mRNA and protein levels
for PPARg, total cell protein lysates were obtained from cells treated with VPA 1, 3, and 5 days after addition of the MDI medium. PPARg has two isoforms (1 and 2) that are undetectable in preadipocytes (day 0), are expressed at low levels one day following initiation of differentiation (day 1), and clearly detectable at all time points tested after day 3 ( Figure 6A ). VPA treatment caused a reduction in PPARg 1 and PPARg 2 , with a maximum reduction greater than 50% on day 7 ( Figure 6C ). After detection of PPARg, blots were stripped and incubated with an antibody against C/EBPa, which detects both the 42 kDa and 30 kDa alternative translation products.
While C/EBPa proteins were undetected in preadipocytes, a signal was detected at day 1 of differentiation, and increased throughout differentiation, days 3-7 ( Figure 6A ). Compared to untreated cells, daily VPA treatment reduced the amount of p42 and p30 C/EBPa protein ( Figure   6C ), which was surprising since no change in C/EBPa mRNA levels were detected in the presence of VPA.
The precursor (P; 125 kDa) and the cleaved (C; 68 kDa) active form of SREBP1a were detected in differentiating adipocytes ( Figure 6B ). In comparison to the expression of the SREBP1a (P), which appears 1 day after inducing differentiation, SREBP1a (C) was detected at later time points, with higher amounts of expression at day 4 and 7. Daily VPA treatment did not have an effect on the amount of SREBP1a (P), but consistently decreased the SREBP1a (C) at day 4 and later time points (Figures 6B & C) .
HDAC inhibition and adipogenesis
We sought to determine whether other HDAC inhibitors had similar effects on adipogenesis and confirm if VPA treatment in our model was associated with HDAC inhibition. Similar to VPA, daily TSA (3 nM) or 4-phenylbutyrate (4-PB; 1.5 mM) treatment inhibited 3T3-L1 differentiation ( Figures 7A, B) . The dose of VPA, TSA, and 4-PB was chosen based on the known HDAC IC 50 for these compounds (3, 4, (18) (19) (20) . For hydroxamic acid compounds such as Figure 7D ). Some histone H3 acetylation was observed in VPM treated cells, but the levels were consistently less than that produced by VPA or TSA ( Figure 7D ).
We determined whether the reduction in adipocyte differentiation by TSA affected C/EBPa, PPARg, and SREBP1a protein and mRNA expression. TSA reduced PPARg 1 , PPARg 2 , p42 and p30 C/EBPa, and the cleaved form of SREBP1a (C) but not SREBP1a (P) (Figures 8A & B) . In contrast to the effects of VPA or TSA, VPM treatment, which does not inhibit differentiation, did not affect protein expression ( Figure 8A ). Similar to VPA treated cells, TSA treatment caused reduced levels of PPARg (average reduction 23±7%) and SREBP1a (average reduction 18±11%) mRNA levels ( Figure 8C ). Unlike VPA treatment, which had no effect on C/EBPa mRNA levels, TSA treatment reduces C/EBPa mRNA levels (average reduction 37±5%), and VPM had no effect on mRNA levels compared to UT treated cells ( Figure 8C ). Our results show that VPA treatment prevents mouse and human adipocyte differentiation in vitro. Pharmacologic manipulation of HDAC activity with TSA and 4PB inhibited preadipocyte differentiation, whereas VPM did not, leading to the notion that the HDAC inhibitory properties of VPA may be responsible for blocking adipogenesis. TSA treatment reduced mRNA levels for PPARg, C/EBPa, and SREBP1a, whereas VPA treatment reduced PPARg and SREBP1a mRNA, but not C/EBPa mRNA levels. Inhibition of differentiation by VPA and TSA was accompanied by a reduction in TAG and decreased protein levels for PPARg, C/EBPa, and SREBP1a. Based on these results we hypothesize that HDAC activity is required for adipocyte differentiation.
Discussion
The role of HDACs during adipocyte differentiation remains largely unknown compared to their role in the differentiation of other cell types such as skeletal muscle (21) . In models of muscle cell differentiation (C2C12 skeletal muscle cells and human skeletal myoblasts) when HDAC inhibitors were added one day prior to the differentiation-inducing medium they (40) and in vivo, mice with disrupted C/EBPa expression shown a reduction in PPARg levels (41) . We see a striking reduction in C/EBPa protein levels with VPA treatment despite no affect on C/EBPa mRNA levels. It remains to be determined whether VPA decreases C/EBPa protein translation or enhances degradation. Since this effect is observed with VPA but not TSA, it is unlikely to be mediated by HDAC inhibition. This suggests that VPA has multiple mechanisms of action to abrogate adipogenesis.
In contrast to our work, others have suggested that HDAC inhibitors promote the differentiation of adipocytes by enhancing the transactivation of PPARg and C/EBPa (13,25). We examined VPA effects on adipogenesis with the initial aim of understanding how VPA may induce weight gain in patients. Both fat cell number controlled by preadipocyte proliferation and adipogenesis, and fat cell size controlled by lipogenesis contribute to weight gain. We hypothesized that VPA would enhance adipogenesis, however, we found that VPA does the opposite. It is paradoxical that in vitro VPA inhibits adipogenesis yet in vivo induces weight gain. Weight gain is the outcome of a variety of central and peripheral inputs and we hypothesize that VPA affects numerous cell types in the central nervous system and periphery. In vivo, VPA suppression of adipogenesis may be overcome by compensatory physiological effects with the net outcome of weight gain. Lithium carbonate, another mood stabilizer that induces weight gain in vivo, inhibits adipogenesis in vitro most likely through its effects on Wnt/GSK3ß signaling (43, 44) . Unlike lithium carbonate, we suggest that VPA inhibition of adipocyte differentiation is due to its HDAC inhibitory activity. VPA has recently been shown to produce some of its neuronal effects through reduction of inositol biosynthesis, which can be blocked by supplementing cells with inositol. We found that inositol supplementation was unable to reverse the ability of VPA to inhibit adipogenesis 8 . Moreover VPA is unlikely to mediate its effects via a direct activation of PPARg. Overall our results highlight a role for HDAC activity in adipogenesis that can be blocked by treatment with VPA. 
